Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report report published on Monday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of Eagle Pharmaceuticals stock opened at $1.25 on Monday. The firm has a 50 day simple moving average of $1.25 and a 200 day simple moving average of $0.95. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $6.37.

Hedge Funds Weigh In On Eagle Pharmaceuticals

A hedge fund recently raised its stake in Eagle Pharmaceuticals stock. DGS Capital Management LLC grew its holdings in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 44.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 71,728 shares of the specialty pharmaceutical company’s stock after purchasing an additional 22,239 shares during the quarter. DGS Capital Management LLC owned approximately 0.55% of Eagle Pharmaceuticals worth $268,000 at the end of the most recent reporting period. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.